Larimar Therapeutics, Inc. (LRMR)
3.83
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
3.85
+0.02
(+0.52%)
After-Hours: 20:00
Larimar Therapeutics Research and Development Expense (Quarterly) : 27.94M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.94M |
| March 31, 2026 | 24.97M |
| December 31, 2025 | 59.29M |
| September 30, 2025 | 44.84M |
| June 30, 2025 | 23.28M |
| March 31, 2025 | 26.46M |
| December 31, 2024 | 26.66M |
| September 30, 2024 | 13.84M |
| June 30, 2024 | 19.60M |
| March 31, 2024 | 12.86M |
| December 31, 2023 | 10.57M |
| September 30, 2023 | 6.516M |
| June 30, 2023 | 5.826M |
| March 31, 2023 | 4.508M |
| December 31, 2022 | 7.186M |
| September 30, 2022 | 5.505M |
| June 30, 2022 | 5.563M |
| March 31, 2022 | 5.724M |
| December 31, 2021 | 6.204M |
| September 30, 2021 | 13.94M |
| June 30, 2021 | 9.025M |
| March 31, 2021 | 8.901M |
| December 31, 2020 | 10.51M |
| September 30, 2020 | 6.869M |
| June 30, 2020 | 8.907M |
| Date | Value |
|---|---|
| March 31, 2020 | 4.984M |
| December 31, 2019 | 5.386M |
| September 30, 2019 | 8.014M |
| June 30, 2019 | 3.128M |
| March 31, 2019 | 9.631M |
| December 31, 2018 | 11.76M |
| September 30, 2018 | 12.03M |
| June 30, 2018 | 12.31M |
| March 31, 2018 | 13.93M |
| December 31, 2017 | 11.81M |
| September 30, 2017 | 9.923M |
| June 30, 2017 | 10.73M |
| March 31, 2017 | 9.677M |
| December 31, 2016 | 7.275M |
| September 30, 2016 | 9.421M |
| June 30, 2016 | 10.36M |
| March 31, 2016 | 12.60M |
| December 31, 2015 | 17.71M |
| September 30, 2015 | 14.17M |
| June 30, 2015 | 12.53M |
| March 31, 2015 | 10.22M |
| December 31, 2014 | 7.345M |
| September 30, 2014 | 12.08M |
| June 30, 2014 | 4.742M |
| March 31, 2014 | 3.275M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 6.272M |
| Marker Therapeutics, Inc. | 1.476M |
| Rezolute, Inc. | 11.41M |
| Krystal Biotech, Inc. | 13.16M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |